Evidence map›Paper›PMID 36899203›Full record

ArticleBulletin of experimental biology and medicine2023

Changes in Oncogene Expression in Experimental Glioblastoma 101.8 Rats during Therapy with PLGA Nanoparticles Loaded with Doxorubicin.

A I Alekseeva, A D Gerasimov, V V Kudelkina, N S Osipova, S F Drozd, G V Pavlova, A M Kosyreva, T Kh Fatkhudinov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Rat Glioma 101.8 Tissue Strain: Molecular and Morphological Features.International journal of molecular sciences · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

A I AlekseevaB. V. Pet-rovsky Russian Research Center of Surgery, A. P. Avtsyn Research Institute of Human Morphology, Moscow, Russia. mariott@bk.ru.
A D GerasimovB. V. Pet-rovsky Russian Research Center of Surgery, A. P. Avtsyn Research Institute of Human Morphology, Moscow, Russia.
V V KudelkinaB. V. Pet-rovsky Russian Research Center of Surgery, A. P. Avtsyn Research Institute of Human Morphology, Moscow, Russia.
N S OsipovaD. I. Mendeleev University of Chemical Technology of Russia, Moscow, Russia.
S F DrozdN. N. Burdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, Moscow, Russia.
G V PavlovaInstitute of Higher Nervous Activity and Neurophysiology, Moscow, Russia.
A M KosyrevaB. V. Pet-rovsky Russian Research Center of Surgery, A. P. Avtsyn Research Institute of Human Morphology, Moscow, Russia.
T Kh FatkhudinovB. V. Pet-rovsky Russian Research Center of Surgery, A. P. Avtsyn Research Institute of Human Morphology, Moscow, Russia.
Research Institute of Human Morphology · RUMinistry of Health of the Russian Federation · RUD. Mendeleyev University of Chemical Technology of Russia · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compared the expression of the main glioblastoma oncogenes during therapy with doxorubicin (Dox) and Dox in nanoparticles based on a copolymer of lactic and glycolic acids (Dox-PLGA) at a delayed start of treatment. Late initiation of Dox-PLGA therapy of glioblastoma showed an increase in the expression of multiple drug resistance genes, such as Abcb1b and Mgmt, and a decrease in Sox2 expression. Increased expression of other oncogenes (Melk, Wnt3, Gdnf, and Pdgfra) were observed during both Dox and Dox-PLGA therapy. These changes indicate increased tumor aggressiveness and its resistance to cytostatics at the late start of therapy.

Indexed as

DoxorubicinGlioblastomaNanoparticlesAnimalsCell Line, TumorDisease Models, AnimalDrug CarriersOncogenesPharmacogenomic TestingPolylactic Acid-Polyglycolic Acid CopolymerRatsDoxorubicinDrug CarriersPolylactic Acid-Polyglycolic Acid CopolymerdoxorubicinDox-PLGAglioblastoma 101.8multidrug resistanceSox2

Identifiers

PMID36899203
OpenAlexW4323921026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.